Host: Javed Butler, MD, MBA, MPH <br>

  Guest: Scott Solomon, MD <br>


  
    <p>Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction (DELIVER trial) is a study designed to assess the effectiveness of SGLT2 inhibitors in patients with higher left ventricular ejection fraction. To help lead the discussion on the results of this study, Dr. Javed Butler is joined by Dr. Scott Solomon, lead study author and Director of the Clinical Trials Outcomes Center and the Edward D. Frohlich Distinguished Chair at Harvard Medical School. </p>

A Look into the Effectiveness of Dietary Supplements

Since cardiovascular disease is one of the leading causes of death in the U.S., cardiology physicians are continuously working to better understand this common disease and to help patients improve their heart health. And here to assist cardiology physicians in this mission is Heart Matters, a series dedicated to covering essential strategies and research efforts focusing on all types of heart problems, including coronary artery diseases, heart attacks, high cholesterol, high blood pressure, and more.
So whether you’re looking for ways to improve heart health or catch up on the latest cardiology research, you never have to worry about missing a beat thanks to Heart Matters.

Uncovering the Results of the DELIVER Trial